MedTrace Logo

Mometasone Furoate Aqueous (MK-0887/SCH 032088) Nasal Spray vs Placebo and FLONASE® in Seasonal Allergic Rhinitis Patients (I94-001)

NCT03882047 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 313

Last updated 2022-02-09

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy and safety of mometasone furoate (SCH 32088) aqueous nasal spray 200 mcg once daily compared to placebo once daily in the treatment of participants with seasonal allergic rhinitis. Flonase (fluticasone propionate) nasal spray 200 mcg once daily has been chosen as the active control for this study.

Conditions

  • Rhinitis, Allergic, Seasonal

Interventions

DRUG

Mometasone furoate

Mometasone furoate nasal spray, 200 mg once daily

DRUG

Fluticasone propionate

Fluticasone propionate nasal spray, 200 mg once daily

DRUG

Mometasone furoate placebo

Mometasone furoate placebo matching nasal spray, once daily

DRUG

Fluticasone propionate placebo

Fluticasone propionate placebo matching nasal spray, once daily

Sponsors & Collaborators

  • Organon and Co

    lead INDUSTRY

Principal Investigators

  • Medical Director · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1994-08-11
Primary Completion
1994-09-16
Completion
1994-09-16

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03882047 on ClinicalTrials.gov